liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease
Umeå University, Sweden .
Östergötlands Läns Landsting, Center of Paediatrics and Gynaecology and Obstetrics, Department of Paediatrics in Linköping. Children's Heart Centre, Lund, Sweden .
Sahlgrenska University Hospital, Gothenburg, Sweden.
Astrid Lindgren Childrens Hospital, Stockholm, Sweden.
Show others and affiliations
2014 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227, Vol. 103, no 8, 840-845 p.Article in journal (Refereed) Published
Abstract [en]

Aim: This is the first study to evaluate compliance with the 2003 Swedish national guidelines for prophylactic treatment of respiratory syncytial virus (RSV) in children with congenital heart disease (CHD). We estimated the relative risk (RR) of children with CHD being hospitalised with a RSV infection, studied the extent to which RSV prophylactic treatment with palivizumab corresponded to the guidelines and determined the morbidity of children with CHD who developed RSV infection despite prophylaxis.

Methods: This national observational study comprised prospectively registered data on 219 children with CHD treated with palivizumab, medical records on RSV cases and information on hospitalisation rates of children with CHD and RSV infection.

Results: The calculated RR of children with CHD being hospitalised with RSV infection was 2.06 (950/0 Cl 1.6-2.6; p less than 0.0001) compared with children without CHD. Approximately half of the patients (49%) born before the RSV season and 25% born during the RSV season did not start treatment as recommended by the guidelines.

Conclusion: Having CHD increased the rate and estimated RR of children being hospitalised with RSV infection. The guidelines were not followed for about half of the children born before a RSV season and a quarter of the children born during a RSV season and need updating.

Place, publisher, year, edition, pages
Wiley-Blackwell, 2014. Vol. 103, no 8, 840-845 p.
Keyword [en]
Congenital heart disease; Palivizumab; Prophylaxis; Respiratory syncytial virus; Swedish national guidelines
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:liu:diva-109873DOI: 10.1111/apa.12658ISI: 000339986800009PubMedID: 24724913OAI: oai:DiVA.org:liu-109873DiVA: diva2:741627
Note

Funding Agencies|Abbott (EUDRACT) [AIF-11-0003]

Available from: 2014-08-28 Created: 2014-08-28 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Paediatrics in Linköping
In the same journal
Acta Paediatrica
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 196 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf